ライフサイエンスコーパス: portal vein

1 a double perfusion of the hepatic artery and portal vein.

2 abscess cavity along with thrombosis of left portal vein.

3 ozotocin-induced diabetic mice (H-2) via the portal vein.

4 f gas in the mesenteric veins but not in the portal vein.

5 tion-versus-time curves in the liver and the portal vein.

6 the mixed tracer input to the liver via the portal vein.

7 ndard) islets from BALB/c (H-2) mice via the portal vein.

8 oppler ultrasonography was used to check the portal vein.

9 ed bile acids are delivered to the liver via portal vein.

10 se-contrast images were also acquired in the portal vein.

11 S allowed blood samples to be taken from the portal vein.

12 V) joining with the splenic vein to form the portal vein.

13 er to host epithelial tissue and the hepatic portal vein.

14 rointestinal (GI) tract to the liver via the portal vein.

15 r above, below, and at the level of the main portal vein.

16 supply comes from the intestine through the portal vein.

17 ated CpG containing DNA to the liver via the portal vein.

18 y excretion, and the signal intensity in the portal vein.

19 between hepatic artery or its branch and the portal vein.

20 ity of noncancerous liver is supplied by the portal vein.

21 ameter of paraumbilical vein and diameter of portal vein.

22 n when islet cells are transplanted into the portal vein.

23 ic vein to the umbilical portion of the left portal vein.

24 e diameter of the paraumbilical vein and the portal vein.

25 that occurs when islets are infused into the portal vein.

26 d at least one injury, most commonly a short portal vein (21.5%).

27 Results Occlusion was identified in 39.7% of portal veins (29 of 73), 15.0% of hepatic veins (six of

28 the CBD decreased to 62% after clamping the portal vein, 51% after clamping the hepatic artery, and

29 g infusion, SHAPE data were collected from a portal vein and a hepatic vein, and the difference was c

30 eedle was advanced transhepatically into the portal vein and as many as four 7.5-mL aliquots of blood

31 Portal vein and bile duct area index were significantly

32 Levels of amino acids in the hepatic portal vein and caudal vein were measured at intervals a

33 In the second case, the preduodenal portal vein and hemiazygos continuation with interruptio

34 the dendritic nature of the hepatic artery, portal vein and hepatic vein can be predicted, together

35 ernative porto-caval shunt between the right portal vein and inferior vena cava detected on postnatal

36 ically significant difference in diameter of portal vein and number of collateral channels was found

37 systemic collateral channels and diameter of portal vein and positive correlation between diameter of

38 However, the contribution of the portal vein and the gastroduodenal artery to the bile du

39 ever, the liver receives blood from both the portal vein and the hepatic artery, with the peak of the

40 lanted with 350 syngeneic islets through the portal vein and treated once-daily with either rapamycin

41 peared ischemic with a flattened right lobar portal vein and vena cava without any visible active ble

42 ugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were a

43 , 17 (17.3%) had cavernous transformation of portal vein, and 3 (3.1%) had post-transplant thrombosis

44 This study emphasizes the importance of the portal vein, and disturbances in portal venous blood flo

45 Attenuation of aorta, main portal vein, and liver were measured.

46 vels were also determined from hepatic vein, portal vein, and systemic arterial blood in seven patien

47 d texture mapping of tumors, hepatic artery, portal vein, and the hepatic veins was developed.

48 of vagal nerve supply to the liver, hepatic portal vein, and the proximal duodenum provided by the c

49 from the gastrointestinal tract through the portal vein, and thereby is exposed continuously to diet

50 expressions were both decreased in Dicer KO portal veins, and inhibition of L-type channels in contr

51 resistant to vessel occlusion compared with portal veins, and only arterial patency within an ablati

52 Portal vein angioplasty/stenting is conventionally perfo

53 arge amounts of unmodified folic acid in the portal vein are probably attributable to an extremely li

54 A portal vein area index <0.08 had a lower chance of succe

55 Low portal vein area index and intraoperative portal blood i

56 the intestinal mucosa and transferred to the portal vein as the natural circulating plasma folate, 5-

57 ivers perfused with autologous blood via the portal vein at 60, 70, 80, 90, and 100 mL/min per 100 g

58 model perfused with autologous blood via the portal vein at five flow rates (60, 70, 80, 90, and 100

59 radient, defined as the gradient between the portal vein at the site downstream of the site of obstru

60 model perfused with autologous blood via the portal vein at three flow rates (60, 80, 100 mL/min per

61 (every 6 months) were performed to check the portal vein axis.

62 ially relatively sparse mesh surrounding the portal vein becomes five-fold denser through elongation,

63 iver communicates with the intestine via the portal vein, biliary system, and mediators in the circul

64 sectable PBCs had a mean of 83.2 CTCs/7.5 mL portal vein blood (median, 62.0 CTCs/7.5 mL portal vein

65 There were no complications from portal vein blood acquisition.

66 We identified CTCs in all portal vein blood samples from patients with PBCs, but l

67 portal vein blood (median, 62.0 CTCs/7.5 mL portal vein blood).

68 BCs had a mean of 118.4 +/- 36.8 CTCs/7.5 mL portal vein blood, compared with a mean of 0.8 +/- 0.4 C

69 val index, tooth mobility; liver status, and portal vein caliber by ultrasound examination; bone retr

70 develop early after LT, the occlusion of the portal vein can have catastrophic consequences to the gr

71 ein (SMV) and/or portal vein (hereafter, SMV/portal vein) contact (r = -0.38), and post-CRT superior

72 Portal vein CTCs can be used for molecular characterizat

73 In a selected patient, portal vein CTCs were found to carry the same mutations

74 f 21 patients with target tumors adjacent to portal veins developed mild to moderate cholestasis 2-6

75 OR:1.3; 95%CI:1.2-1.5; p < 0.001), increased portal vein diameter (OR:1.2; 95%CI: 1.07-1.4; p = 0.003

76 No significant difference in age and portal vein diameter was found in these groups.

77 l shunts and their relationship with age and portal vein diameter.

78 Abdominal ultrasonography and portal vein doppler ultrasonography were performed in19

79 as measured at baseline, during clamping the portal vein, during clamping the hepatic artery, and dur

80 epatectomy (0%, 3%, 4%, P < 0.001), need for portal vein embolization (5%, 9%, 9%, P = 0.001), preope

81 the clinical outcome of patients undergoing portal vein embolization (PVE) and autologous CD133 bone

82 m of this retrospective study was to compare portal vein embolization (PVE) and radiologica simultane

83 ient size of the future liver remnant (FLR), portal vein embolization (PVE) of the tumor-bearing live

84 After portal vein embolization (PVE), 15% of patients remain i

85 Preoperative portal vein embolization has thus far been established a

86 Portal vein embolization improves the safety of liver re

87 Portal vein embolization is associated with increased TG

88 Portal vein embolization is used to increase future remn

89 comorbidities, hepatic function, ASA class, portal vein embolization rate)(p > 0.05).

90 Portal vein embolization was performed in 28 patients di

91 patic vascular occlusion (rate or duration), portal vein embolization, drain use, etc.)(p > 0.05).

92 herapies are transcatheter therapies such as portal vein embolization, hepatic artery infusion chemot

93 phasizing the importance of measures such as portal vein embolization, hepatic pedicle clamping and p

94 r: strategy, stage of the procedure, access, portal vein embolization, if used, types of transection

95 d strategies for utilization of preoperative portal vein embolization, transjugular intrahepatic port

96 h conventional 2-stage hepatectomy including portal vein embolization.

97 is effective reliably even after failure of portal vein embolization.

98 ce were elevated CA 19-9 (HR 1.8; P = 0.01), portal vein encasement (HR 3.3; P = 0.007), and residual

99 These changes seemed to result in enhanced portal vein endotoxin concentrations and fatty liver dis

100 sion Unlike monopolar RF ablation, change in portal vein flow rates does not have a statistically sig

101 rpose To investigate the effect of change in portal vein flow rates on the size and shape of ablation

102 s a reduction in hepatic artery flow volume, portal vein flow volume and total flow volume that was n

103 s used to examine portal vein peak velocity, portal vein flow volume, hepatic artery resistive index

104 pectrometry with (ii) direct sampling of the portal vein following an intravenous glucose/arginine ch

105 eratively, blood samples were taken from the portal vein for measurement of CTCs before and immediate

106 During somatostatin and basal portal vein glucagon infusion, insulin was infused porta

107 events mediating the pleiotropic actions of portal vein glucose (PoG) delivery on hepatic glucose di

108 ycemia plus either 4x basal insulin (INS) or portal vein glucose infusion (PoG) was measured.

109 synthesis during hyperinsulinemia or hepatic portal vein glucose infusion in vivo.

110 mic clamp was established in the presence of portal vein glucose infusion.

111 lycemic-hyperinsulinemic challenge including portal vein glucose infusion.

112 Specifically, it is unlikely that a hepatic portal vein glucose sensor signaling RYGB-induced increa

113 4 of the middle hepatic vein trunk) and left portal vein graft to the recipient inferior mesenteric v

114 tially sensing glucose levels in the hepatic portal vein has recently been suggested in a mouse model

115 s in the ratio of insulin to glucagon in the portal vein have a major role in the dysregulation of he

116 Clinical status, portal vein hemodynamics, morphology of the liver, de no

117 measured systemic and regional hemodynamics (portal vein, hepatic and right kidney artery ultrasound

118 measured systemic and regional hemodynamics (portal vein, hepatic and right kidney artery ultrasound

119 Complete occlusion of the portal veins, hepatic veins, and hepatic arteries within

120 nge in superior mesenteric vein (SMV) and/or portal vein (hereafter, SMV/portal vein) contact (r = -0

121 Portal vein hypertension (PVH) in liver cirrhosis compli

122 uity with the inferior mesenteric artery and portal vein in continuity with the inferior mesenteric v

123 sential amino acids over time in the hepatic portal vein in contrast to that of the non-selected stra

124 anted into mdr2(-/-) mice livers through the portal vein in the presence or absence of GTN.

125 echnique, with immediate transplantation via portal vein infusion.

126 d islets were transplanted into patients via portal vein infusion.

127 (residues 331-580) into permeabilized rabbit portal vein inhibited Ca2+ sensitized force and activati

128 livers exposed to the same three patterns of portal vein insulin delivery by use of sequential liver

129 Using a pancreatic clamp, hepatic portal vein insulin delivery was increased three- or eig

130 Thus small increments in portal vein insulin have major consequences on the liver

131 ere as follows: variant entrance of the main portal vein into the liver and atypically located superi

132 re (P = .022), tumor burden (P < .001), main portal vein invasion (P = .033), and arterioportal shunt

133 lobar, bilobar), tumor burden (</=50%, 50%), portal vein invasion (present, absent), and arterioporta

134 [69.4% sessions (n = 77)] or B; ascites and portal vein invasion was present in 18 (16.2%) and 15 (1

135 the setting of hepatocellular carcinoma with portal vein invasion, and for radiation segmentectomy.

136 ic structure, tumor burden greater than 50%, portal vein invasion, and shunting had confirmed associa

137 ulsatile insulin secretion delivered via the portal vein is important for hepatic insulin action and,

138 The portal vein is inaccessible in humans, and methods of es

139 nce whether measured at the upper, lower, or portal vein levels within the right lobe of the liver.

140 , CCl(4)-induced ascitic cirrhosis and 2-day portal vein-ligated (PVL) animals.

141 Sham, portal vein-ligated (PVL), and 4-week biliary duct-ligat

142 We induced prehepatic PH by partial portal vein ligation (PPVL) in germ-free (GF) or mice co

143 Associating liver partition and portal vein ligation (PVL plus transection=ALPPS) or the

144 Portal vein ligation (PVL) induces liver growth prior to

145 ALPPS combines portal vein ligation (PVL) with liver transection (step

146 ing partial hepatectomy (PH), intraoperative portal vein ligation (PVL), and associated liver partiti

147 the first step, surgical exploration, right portal vein ligation (PVL), and in situ splitting (ISS)

148 ation after extended partial hepatectomy and portal vein ligation for multiple bilobar CRLM were appl

149 Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) has

150 djustment in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) occu

151 on (PVL), and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) show

152 Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), a 2

153 tality after Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS), ava

154 edure ALPPS (Associating Liver Partition and Portal Vein Ligation for Staged hepatectomy).

155 radiological associating liver partition and portal vein ligation for staged hepatectomy." RASPE indu

156 r regeneration after partial hepatectomy and portal vein ligation, and increased the expression of ce

157 d portal hypertension was induced by partial portal vein ligation.

158 ss-severe forms of portal hypertension after portal vein ligation.

159 Cl4 intoxication) and non-cirrhotic (partial portal vein ligation/PPVL) rats received either atorvast

160 n liver injury or KC activation, even though portal vein LPS levels were elevated.

161 creased intestinal permeability and elevated portal vein LPS levels, evidence of hepatocyte injury an

162 r to those obtained after cannulation of the portal vein main stem.

163 donor livers is typically performed via the portal vein main stem.

164 nt a left hepatectomy with ligation of right portal vein maintaining the right hepatic artery patent.

165 Twenty-four of these showed bactDNA in the portal vein, matching peripheral blood-identified bactDN

166 g the dual-input time-activity curve without portal vein measurements are being developed.

167 eased in HCC tissue specimens, especially in portal vein metastasis or intrahepatic metastasis, compa

168 n patients (58%) had borderline or increased portal vein minimum and maximum flow velocities.

169 artery, superior mesenteric artery, and main portal vein (MPV).

170 cially on thrombotic total occlusion of main portal vein (MPV).

171 ons for MesoRex bypass (MRB) in extrahepatic portal vein obstruction and the role of primary prophyla

172 Liver cirrhosis but also portal vein obstruction cause portal hypertension (PHT)

173 Therefore, children with extrahepatic portal vein obstruction should be offered MRB for primar

174 vast majority of children with extrahepatic portal vein obstruction will experience complications th

175 In portal vein obstruction, statins enhanced the canonical

176 Portal vein occlusion (PVO) was used in 44 patients.

177 Of these, 87 (34%) IU patients required portal vein occlusion after chemotherapy downstaging.

178 TSH with portal vein occlusion is an established method for patie

179 requiring 12 or more chemotherapy cycles and portal vein occlusion to achieve resectability, is assoc

180 Portal vein occlusion was only significantly correlated

181 y hepatocytes at concentrations found in the portal vein of animals (60-80 muM).

182 venous sac made from lumbar vein or into the portal vein of syngeneic rats.

183 vasion into the extra-hepatic portion of the portal vein or the development of distant metastases ren

184 immediately adjacent to major hepatic veins, portal veins, or both; thus, they were not considered su

185 e lower level, and was 0.047 +/- 0.10 at the portal vein (P = .02).

186 Two radiologists evaluated portal vein patency and intrahepatic portal branches, th

187 While the difference in portal vein peak velocity in the hepatosteatosis and con

188 Doppler ultrasonography was used to examine portal vein peak velocity, portal vein flow volume, hepa

189 creased clot formation rate, associated with portal vein platelet aggregates and reductions in protei

190 graft with concomitant focus on keeping the portal vein pressure below 20 mm Hg.

191 Portal vein pressure was measured; morphology of the hep

192 ons, especially limited tissue volume due to portal vein pressure.

193 No vascular grafts (VG) were required for portal vein (PV) anastomosis.

194 nderwent 2D phase-contrast MR imaging of the portal vein (PV) and infrahepatic and suprahepatic infer

195 arginal islet dose (150 islets), or into the portal vein (PV) at a full dose (500 islets).

196 Portal vein (PV) complications after living donor liver

197 asound measurement of right (R) and left (L) portal vein (PV) diameters and Urata's standard liver vo

198 human liver transplant recipients both pre- [portal vein (PV) sample] and post-(liver flush; LF) repe

199 Chronic, obliterative portal vein (PV) thrombosis (PVT) represents a relative

200 In case of portal vein (PV) thrombosis (PVT), renoportal anastomosi

201 or mesenteric vein (SMV), splenic vein (SV), portal vein (PV), and the TIPS.

202 t of PVT patients requiring nonphysiological portal vein reconstruction was associated with higher co

203 ts, and direct-acting anticoagulants improve portal vein repermeation vs observation alone.

204 performed in 54% of cases, with arterial and portal vein resections in 15% and 32%, respectively.

205 covered extrinsic compression of hepatic and portal veins, resulting in functional Budd-Chiari syndro

206 erapy, transcatheter arterial therapies, and portal vein revascularisation.

207 For the 5 patients with complete portal vein revascularization who underwent lobar hepate

208 We detected CTCs in portal vein samples from all 18 patients (100%) vs perip

209 Measurement of insulin levels in the portal vein showed a time window of absorption that was

210 in phasic smooth muscle tissues, such as the portal vein, small intestine, and small mesenteric arter

211 ing bleeding EV complicated by gastric, main portal vein, splenic mesenteric junction, and splenic ve

212 clerosing agent was also present in the main portal vein, splenic mesenteric junction, and splenic ve

213 thrombosis (nonsignificant [NS]), and one of portal vein stenosis (NS).

214 Portal vein stenosis (PVS) or thrombosis (PVT) are uncom

215 Persistence of SMV/portal vein stenosis after CRT was not predictive of R1

216 Portal vein stent placement via segment 4 of the portal

217 al vein stent placement via segment 4 of the portal vein stump was performed from the inferior mesent

218 area, total lumen area, and diameter of main portal vein, superior mesenteric vein, and splenic vein.

219 x 2 cm x 2.1 cm in size with abutment of the portal vein-superior mesenteric vein confluence for less

220 gh pancreaticoduodenectomy (PD) with en-bloc portal vein/superior mesenteric vein (PV/SMV) resection

221 at low metformin concentrations found in the portal vein suppress glucose production in hepatocytes t

222 and soluble factors circulating through the portal vein system by releasing tremendous amounts of di

223 bursts at ~5-min intervals into the hepatic portal vein, these pulses being attenuated early in the

224 e review the common and distinct features of portal vein thromboses in patients without liver tumors,

225 were mainly rejected for comorbidity (19%), portal vein thrombosis (16%), previous surgery (9%), obe

226 ently in OPV than in cirrhosis: extrahepatic portal vein thrombosis (18 [43%] of 42 vs five [12%] of

227 s of the liver in children with extrahepatic portal vein thrombosis (EHPVT), with surgical outcome af

228 pared with non-BCS liver recipients), one of portal vein thrombosis (nonsignificant [NS]), and one of

229 Portal vein thrombosis (PVT) and different cardiovascula

230 patients of liver cirrhosis associated with portal vein thrombosis (PVT) can be effectively treated

231 In cirrhosis, portal vein thrombosis (PVT) could be a cause or a conse

232 low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced c

233 Portal vein thrombosis (PVT) is common in patients with

234 Nonneoplastic portal vein thrombosis (PVT) is frequent in patients wit

235 Portal vein thrombosis (PVT) occurs frequently in hepato

236 ate and survival of hepatocellular carcinoma portal vein thrombosis (PVT) patients treated with (90)Y

237 ed-stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with (90)Y radioemb

238 onths with no significant difference between portal vein thrombosis (PVT) versus no PVT (7 versus 13

239 The 1-year probability of developing portal vein thrombosis (PVT) was 9%, and 53% of patients

240 tients with chronic noncirrhotic, nontumoral portal vein thrombosis (PVT), the usually recommended st

241 ocellular carcinoma (HCC), including 16 with portal vein thrombosis (PVT), were treated with (90)Y-lo

242 yndrome (BCS) and nonmalignant, noncirrhotic portal vein thrombosis (PVT).

243 leeding from portal hypertension but also by portal vein thrombosis (PVT).

244 ion (Budd-Chiari Syndrome) and in those with portal vein thrombosis (second section); and we briefly

245 lenectomy was associated with development of portal vein thrombosis after surgery (P = 0.01).

246 ther evaluations revealed a mild ascites and portal vein thrombosis although the patient received pro

247 wo (16.3%) patients developed pre-transplant portal vein thrombosis and its presence had no impact in

248 iagnosis and management of acute symptomatic portal vein thrombosis are essential.

249 Left sided abscess and portal vein thrombosis are rare and hence reported.

250 Portal vein thrombosis at listing was not associated wit

251 Portal vein thrombosis at LT is associated with early (9

252 We aimed to characterize the pre-transplant portal vein thrombosis in a cohort of liver transplant r

253 We speculated that the underlying cause of portal vein thrombosis in our case was coronaviruses.

254 Management of portal vein thrombosis in patients with cirrhosis is mor

255 Portal vein thrombosis is a frequent complication in end

256 In patients with cirrhosis, development of portal vein thrombosis is often insidious and remains un

257 Segmental left portal vein thrombosis occurred in 1 patient and intralu

258 Portal vein thrombosis unrelated to solid malignancy is

259 Portal vein thrombosis was independently associated with

260 e lab data regarding the secondary causes of portal vein thrombosis were normal.

261 as hepatorenal syndrome, hepatichydrothorax, portal vein thrombosis, and Budd-Chiari syndrome.

262 analysis Child-Pugh score, presence of HCC, portal vein thrombosis, and lack of secondary prophylaxi

263 e II diabetes mellitus, renal insufficiency, portal vein thrombosis, and poor performance status.

264 tis/cholecystitis, pancreatitis, hemorrhage, portal vein thrombosis, bowel wall perforation, or dehyd

265 ing for age, sex, treatment, tumor size, and portal vein thrombosis.

266 source of infection and presenting with left portal vein thrombosis.

267 ut was present in 62.5% of the patients with portal vein thrombosis.

268 a higher change of complications related to portal vein thrombosis.

269 There was no incidence of hepatic artery or portal vein thrombosis.

270 y independent risk factor for pre-transplant portal vein thrombosis.

271 e the relationship between folate status and portal vein thrombosis.

272 Three (2.9%) grafts were lost due to portal vein thrombosis.

273 as associated with an increased incidence of portal-vein thrombosis, as compared with placebo.

274 and the hepatic artery, with the peak of the portal vein time-activity curve being delayed and disper

275 Portal vein tissue displays a severalfold decrease in pa

276 y the epithelial layer or by transit via the portal vein to the liver where they can have additional

277 from the gastrointestinal tract through the portal vein to the liver.

278 e hepatic artery, gastroduodenal artery, and portal vein to the microvascular blood flow in the commo

279 ver transplantation, the contribution of the portal vein to the microvascular blood flow through the

280 to a 50-year-old man weighing 92 kg, and the portal vein to the right remnant liver was closed.

281 ents with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) is 2-6 months; conve

282 Portal vein tumor thrombus (PVTT) is strongly correlated

283 eport that TMED3 was up-regulated in HCC and portal vein tumor thrombus.

284 venous system and subsequently develop into portal vein tumour thrombosis (PVTT).

285 management of hepatocellular carcinoma with portal vein tumour thrombosis between the east and the w

286 management of hepatocellular carcinoma with portal vein tumour thrombosis in the east and in the wes

287 Portal vein tumour thrombosis is common among patients w

288 Most anatomical anomalies except portal vein type D/E were acceptable at high-volume cent

289 ascites, splenomegaly, portal hypertension (portal vein velocity, 3.9-5.6 cm/sec of hepatopetal flow

290 Presence of tumor thrombi in the portal veins (venous metastases) is a clinicopathologica

291 mechanism located in the liver and/or in the portal vein wall.

292 ial regression of tumor contact with the SMV/portal vein was associated in all cases with R0 resectio

293 THF, only 4 +/- 18% of labeled folate in the portal vein was unmodified 5-FormylTHF, and the rest had

294 80 +/- 12% of labeled folate in the hepatic portal vein was unmodified folic acid.

295 protocol (P </= .04), but CNRs for liver and portal vein were similar (P = .54 and .73, respectively)

296 ormation is a rare congenital anomaly of the portal vein where the portal blood bypasses the liver.

297 tocytes are usually infused into the hepatic portal vein with many cells rapidly cleared by the innat

298 nificantly reduced the number of CTCs in the portal vein with no benefit in survival outcomes compare

299 aneous puncture of the left hepatic and left portal vein with subsequent guidewire snaring to perform

300 how well-developed portal triads around most portal veins, with no elevation of serum bilirubin.